Cas:842144-05-2 2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile manufacturer & supplier

Chemical Name:2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile

CAS.NO:842144-05-2

Synonyms:2-(7-Bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile;C-8906;(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile;(7-bromo-7-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile

Molecular Formula:C₁₀H₈BrClN₄

Molecular Weight:299.55400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:54.50000

Exact Mass:297.96200

LogP:2.93318

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(7-Bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(7-bromo-7-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(7-bromo-7-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile Use and application,C-8906 technical grade,usp/ep/jp grade.

Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile manufacturer Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. 2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile supplier The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile vendor Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act. 2-(7-bromo-4-chloro-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile factory The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.